614PCANYON trial results: sevasemten, an investigational fast skeletal myosin inhibitor, reduced muscle damage biomarkers and stabilized function in BMD
C. McDonald, J. Donovan(Healthwise), James E. MacDougall(BioBridges (United States)), E. Niks(Leiden University Medical Center), Michela Guglieri(Muscular Dystrophy UK), D. Castro(University of North Texas), H. Kushlaf(University of Cincinnati Medical Center), Banny S. Wong(UMass Memorial Health Care), J. Statland(University of Kansas Medical Center), K. Mathews(University of Iowa), Vidhyapriya Sreenivasan(University of Colorado Denver), Roxana Donisa Dreghici(Roche (Switzerland)), Nicholas Johnson(Animal and Plant Health Agency), Doris G. Leung(Kennedy Krieger Institute), Rosaline C. M. Quinlivan(National Hospital for Neurology and Neurosurgery), A. Veerapandiyan(Arkansas Children's Hospital), Alan J. Russell(Healthwise), H. Phan(Rare Disease Therapeutics (United States)), A. Connolly(Nationwide Children's Hospital), Atul Varadhachary(Washington University in St. Louis)
Cited by 0
Related Papers
Thalassemia Syndromes
|Unknown|2009|475
Autologous Transplantation of Muscle-Derived CD133+ Stem Cells in Duchenne Muscle Patients
|Cell Transplantation|2007|230
Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy
|Scientific Reports|2017|228
European Surveillance for West Nile Virus in Mosquito Populations
|International Journal of Environmental Research and Public Health|2013|181